Saphnelo (anifrolumab-fnia) / BMS, AstraZeneca - LARVOL DELTA

PHASE 1 STUDY EVALUATING HYDROGEL-FORMULATED UC-MSCS ADMINISTERED SUBCUTANEOUSLY IN ADDITION TO STANDARD OF CARE AS A TREATMENT FOR LUPUS NEPHRITIS (ISN-WCN 2026) - P1 | "Lupus treatment relies on the use of glucocorticoids and conventional immunosuppressants (e.g. methotrexate, azathioprine, or mycophenolate mofetil) and targeted therapies (e.g. belimumab, anifrolumab, or voclosporin) to control disease activity and prevent relapse...Secondary endpoints include changes from baseline in SLE activity scores, patient-reported QoL measurements and prednisone administrationResults As of Oct...Investigation of the safety and clinical utility of SC-administered hf-UC-MSCs as a treatment for lupus and LN is ongoing. Further conclusions to be based on data collected through Jan., 2026"

Late-breaking abstract • P1 data • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology

Evolving management of SARD-ILD : Current challenges and emerging treatment options for rheumatoid-associated interstitial lung diseases (PubMed, Z Rheumatol) - "Promising results from ongoing clinical studies provide new therapeutic perspectives for SARD-ILD and PPF and may significantly improve prognosis and disease burden in the future."

Journal • Review • Immunology • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases • Rheumatology

Novel use of anifrolumab in a young patient with Jo-1-positive juvenile dermatomyositis. (PubMed, Rheumatol Adv Pract) - No abstract available

Journal • Dermatomyositis • Immunology • Myositis

Anifrolumab in Refractory Oral Manifestations in Systemic Lupus Erythematosus: A Case Report and Literature Review. (PubMed, Biologics) - "We report the case of a 39-year-old woman with SLE who developed severe, refractory tongue ulcers and glossodynia persisting for three years, unresponsive to hydroxychloroquine (HCQ), azathioprine (AZA), colchicine, methotrexate (MTX), and glucocorticoids (GC). Belimumab was discontinued due to gastrointestinal intolerance and lack of efficacy on oral lesions...While conventional immunosuppressants such as azathioprine, methotrexate, and mycophenolate mofetil remain options, their efficacy for isolated oral lesions is limited...The key learning point is that refractory tongue involvement may represent a dominant and treatment-resistant manifestation of SLE, yet it can respond to targeted biologic therapy such as anifrolumab and our report adds to this growing body of evidence. Prospective comparative studies and registry analyses are required to define anifrolumab's effectiveness specifically for refractory oral manifestations and to compare outcomes with other..."

Journal • Immunology • Inflammatory Arthritis • Lupus • Rheumatology • Systemic Lupus Erythematosus

Rapid response of pyoderma gangrenosum associated with systemic lupus erythematosus to anifrolumab. (PubMed, Med Clin (Barc)) - No abstract available

Journal • Immunology • Inflammatory Arthritis • Lupus • Pyoderma Gangrenosum • Systemic Lupus Erythematosus

Infection Risk Associated With Anifrolumab Versus Traditional Immunosuppressants in Cutaneous Lupus Erythematosus (AAD 2026) - "Anifrolumab users were compared to patients who escalated to methotrexate, azathioprine, or mycophenolate mofetil. Among patients with CLE who progressed beyond hydroxychloroquine, anifrolumab use was associated with a lower two-year infection risk compared to traditional immunosuppressive therapies. These findings support the potential role of anifrolumab in the management of refractory cutaneous lupus."

Cutaneous Lupus Erythematosus • Glomerulonephritis • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Pneumonia • Respiratory Diseases • Septic Shock • Systemic Lupus Erythematosus • IFNAR2

SAPHNELO Systemic Lupus Erythematosus Japan Post-Marketing Surveillance (PMS) (clinicaltrials.gov) - P=N/A | N=1620 | Active, not recruiting | Sponsor: AstraZeneca | Trial completion date: Nov 2025 ➔ Mar 2027 | Trial primary completion date: Nov 2025 ➔ Mar 2027

Trial completion date • Trial primary completion date • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Beyond Skin and Joints: A Multicenter Observational Study on Real-World Effectiveness of Anifrolumab in Hematological Manifestations of Systemic Lupus Erythematosus (EULAR 2026) - No abstract available

Clinical • Observational data • Real-world • Real-world effectiveness • Real-world evidence • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Does Prior Belimumab Use Influence Response to Anifrolumab in Moderate‑to‑Severe SLE? Real‑World Evidence (EULAR 2026) - No abstract available

Clinical • HEOR • Real-world • Real-world evidence • Inflammatory Arthritis

Post-marketing Safety Signals of Anifrolumab: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) (EULAR 2026) - No abstract available

Adverse events • Clinical • P4 data

Spanish Multicenter Real-World Registry of Anifrolumab ANIFRO-Reu) in Systemic Lupus Erythematosus: Efficacy and Safety In patients undergoing up to 12 months of follow-up (EULAR 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

DORIS Remission and LLDAS Attainment in Patients With Systemic Lupus Erythematosus Treated With Subcutaneous Anifrolumab With and Without On-Study Immunosuppressant Use: Post Hoc Analysis of the TULIP-SC Trial (EULAR 2026) - No abstract available

Clinical • Retrospective data • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Achievement and Maintenance of Glucocorticoid Reduction without Increasing Flare Risk in Asian Patients with SLE treated with Anifrolumab: Post-hoc analysis of AZALEA trial (EULAR 2026) - No abstract available

Clinical • Retrospective data • Inflammatory Arthritis

Improved SLE Disease Activity Across Multiple Organ Systems After up to 12 Months of Real-World Treatment With Anifrolumab: Interim Results From the ASTER Study (EULAR 2026) - No abstract available

Clinical • HEOR • Real-world • Real-world evidence • Inflammatory Arthritis

Single-Cell and Spatial Transcriptomic Profiling Reveals Systemic and Tissue Immune Remodeling in SLE Treated with Anifrolumab (EULAR 2026) - No abstract available

Inflammatory Arthritis

Anifrolumab Treatment is Associated With DORIS Remission in Adults With Systemic Lupus Erythematosus: Real-World Outcomes From an Academic Lupus Registry (EULAR 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Anifrolumab versus belimumab in active systemic lupus erythematosus: a propensity score matched analysis. (EULAR 2026) - No abstract available

Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Efficacy of Subcutaneous Anifrolumab Across Multiple Organ Systems in Patients With Moderate to Severe Systemic Lupus Erythematosus: A Post Hoc Analysis of the Phase 3 TULIP-SC Trial (EULAR 2026) - No abstract available

Clinical • P3 data • Retrospective data • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

DORIS Remission and LLDAS Attainment After up to 12 Months of Real-world Anifrolumab Treatment: Interim Results From the ASTER Study (EULAR 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Lupus

Treatment with Anifrolumab Prevents Organ Damage Accrual Compared With Real-world Standard of Care in Patients With Systemic Lupus Erythematosus: Analysis of the LASER Study Over 4 Years (EULAR 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Real-world Effectiveness of Anifrolumab in Systemic Lupus Erythematosus: 12-month Multicenter Data (EULAR 2026) - No abstract available

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

IFN-α-mediated neuronal damage in SLE: Association with neurofilament light chain in SLE and in vitro inhibition by anifrolumab (EULAR 2026) - No abstract available

Preclinical • Inflammatory Arthritis • IFNA1 • NEFL

Anifrolumab treatment in patients with Sjögren's disease: Efficacy and safety assessment in a randomized, double-blind, placebo-controlled phase IIa proof-of-mechanism trial (ANISE-II) (EULAR 2026) - No abstract available

Clinical • P2a data • Sjogren's Syndrome

Real-world use of anifrolumab in genetically confirmed type I interferonopathies: the French experience (EULAR 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Interferonopathies

Real-world evidence prevalence and clinical outcome of patients meeting the inclusion criteria of the Phase 3 Trial DAISY (Detecting effectiveness of Anifrolumab in SSc) - A EUSTAR cohort study. (EULAR 2026) - No abstract available

Clinical • Clinical data • HEOR • P3 data • Real-world • Real-world evidence • Systemic Sclerosis